Kononova, Natalia
Einvik, Gunnar
Holmedahl, Nils Henrik
Hagve, Tor-Arne
Omland, Torbjørn
Søyseth, Vidar
Article History
Received: 4 June 2022
Accepted: 5 September 2022
First Online: 1 November 2022
Declarations
:
: Torbjørn Omland has served on advisory boards for Abbott Diagnostics, roche Diagnostics and Bayer and has received received research support from Abbot Diagnostics, Novartis, Roche Diagnostics,Singulex and SomaLogic via Akershus University Hospital, and speaker’s or consulting honoraria from Roche diagnostics, Simens Healthineers and CardiNor, otherwise none to declare.
: The remaining authors have none conflict of interest to declare.
: “The study protocol was approved by the Regional Medical Ethics Committee (case number 2013/1006/REK Sør-Øst). All participants provided informed written consent prior to the start of the study. All methods were performed in accordance with relevant guidelines and regulations”.
: Not applicable.